Skip to main content

Search

Beating Bad Blood

Beating Bad Blood

The outlook for patients with leukemia and other life-threatening blood cancers* is far more promising than just a generation ago thanks to new targeted treatments, immunotherapies and advancements in blood and marrow transplant. Blood cancers remain a challenging group of diseases, with many types and subtypes. But science has made great strides in diagnosis, transplant and treatment, with additional, promising therapies on the way.

Janssen’s commitment to urgently advancing research and solutions for unmet needs of patients with blood cancers is high. “We have a broad portfolio of blood cancer treatments, and are particularly proud of the work in multiple myeloma”, said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen. “We have been working diligently to develop medicines with new mechanisms of action.”

Addressing the cancer challenge

In oncology, Janssen's goal is to fundamentally alter the way cancer is understood, diagnosed and managed. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and disease interception solutions. These include a focus on hematologic malignancies, prostate cancer and lung cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualized use of our therapies; as well as safe and effective identification and treatment of early changes in the tumor microenvironment. “We still have a long way to go, but each year, the outcomes improve”, concludes Lebowitz.

In September on the occasion of Blood Cancer Awareness month, Janssen will launch the Make Blood Cancer Visible campaign. This campaign aims to get people talking about blood cancer, and to provide a platform for sharing unique and personal insights into what it is like to be diagnosed with, live with, care for, or treat someone with blood cancer.

 

Footnotes:
*Cancers of the blood and lymphatic system include leukemia, lymphoma, and multiple myeloma. The most common blood cancer, leukemia, includes several distinct diseases: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and Chronic myeloid leukemia (CML). Lymphoma is classified into Hodgkin lymphoma and non-Hodgkin lymphoma, which includes mantle-cell lymphoma.